http://www.bioregio-stern.de/en/our-services/corporate-database/insilico-biotechnology-ag (24.05.2013)
Insilico Biotechnology AG
Insilico Biotechnology AG
Insilico Biotechnology designs and optimizes biotech processes for the chemical, pharmaceutical, agricultural and food industries. Insilico boasts internationally recognized expertise and the world’s only system biology platform combining proprietary databases, cell models and computer-controlled evaluation methods. By integrating and evaluating experimental data using genome-wide network models, Insilico offers new solutions for manufacturing biochemicals and biopharmaceuticals, validates active substances and reduces drug development periods. Founded as a spin-off of the University of Stuttgart in 2001, Insilico currently employs eight staff. The company, which was converted into a joint-stock company in July 2006, is headed by Klaus Mauch. Since 2005, Insilico Biotechnology AG as an industrial partner in the federal HepatoSys competence network has been performing computer-based mapping and testing of liver cell metabolism. Insilico is responsible in particular for determining kinetic parameters using supercomputers. The aim is to model a »virtual liver cell« to enable physiological cell processes – such as the breakdown of drugs and toxic substances – to be followed »in silico«. For the second project phase, Insilico will receive Euro 250,000 of funding over the next three years.
| Type | Biotech |
|---|---|
| Management | Klaus Mauch, Dipl.-Ing. |
| Year of foundation | 2001 |
| Employees | 20 |
| Academic board | Prof. Dr. Matthias Reuss |
| Funding | Cash flow |
Insilico Biotechnology AG
Meitnerstraße 8
70569
Stuttgart
Germany
P +49 711 460594-0
F +49 711 460594-10
info [at] insilico-biotechnology [dot] com
http://www.insilico-biotechnology.com/
Contact person
Klaus Mauch